MRD-negative (10^–5) conversion rate from baseline to 12 months of maintenance treatment. ∗Mantel-Haenszel estimate of the common OR for stratified tables is used. The stratification factor is baseline cytogenetic risk per investigator assessment (high vs standard/unknown), as was used for randomization. An OR >1 indicates an advantage for D-R. †P value <.0001, from Fisher exact test. ‡The ITT analysis set was defined as all patients who were randomly assigned to treatment. §Patients who achieved ≥CR at any time during the study per IMWG computerized algorithm. ||The MRD-evaluable analysis set includes all randomly assigned patients who had an MRD assessment at baseline and had ≥1 postbaseline MRD evaluation. ITT, intent to treat.